Anti-Viral Therapies Market Thumbnail Image

2020

Anti-Viral Therapies Market

Anti-Viral Therapies Market Size, Share, Competitive Landscape and Trend Analysis Report by Type, Application and Mechanism of Action : Global Opportunity Analysis and Industry Forecast, 2019-2026

LS : Healthcare

Select an option
Author's: Snehal Manjrekar| and Onkar Sumant | Roshan Deshmukh
Publish Date:

Get Sample to Email

The global anti-viral therapies market size was valued at $38,316.5 million in 2018, and is projected to reach $46,213.4 million by 2026 registering a CAGR of 2.4% from 2019 to 2026.Anti-viral drugs are pharmaceutical products used in treating several viral infections by either eliminating the viral strain or restraining its ability to multiply and replicate within the human body. These drugs find applications in treating various diseases such as influenza, Hepatitis, HIV, and herpes. The use of anti-viral drugs in antiretroviral therapies and influenza anti-viral therapies for treatment of several viral diseases is expected to impact positively on the growth of the anti-viral therapies market. 

Anti-viral-Therapies-Market,-2019-2026_revised

The global antiviral therapies market is majorly driven by increase in the incidence rate of viral infections. In addition, rise in R&D activities and development of newer & advanced formulations, such as vaccines and combination therapy along with pipeline products are expected to propel the market growth. However, high cost involved in the treatment and rise in demand for alternative medicines such as naturopathy and homeopathy are expected to restrain the market growth. On the contrary, development and approvals of combination therapies and growth opportunities in the emerging economies of Asia-Pacific and LAMEA regions are expected to provide numerous opportunities for the market growth during the forecast period.

Global Anti-viral Therapies Market segmentation

The global antiviral therapies market is segmented on the basis of application, type, mechanism of action, and region. Based on application, it is categorized into HIV, hepatitis, herpes, influenza, and other viral diseases. On the basis of type, it is classified into generic drugs and branded drugs. On the basis of mechanism of action, it is divided into nucleotide polymerase inhibitors, reverse transcriptase inhibitors, protease inhibitors, and others. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Application segment review

Based on application, it is categorized into HIV, hepatitis, herpes, influenza, and other viral diseases. HIV segment was the largest revenue contributor to the anti-viral therapies market in 2018 and is expected to continue to this trend during the forecast period, owing to increase in incidences of HIV globally. For instance, as per the data published by UNAIDS, in 2017, around 37 million of the global population is living with HIV. The prevalence of HIV among the adults was estimated to be 0.8%. Therefore, increase in consumption of HIV anti-viral drugs for combating infection is the major factor that drives the growth of anti-viral therapies market for HIV segment.

Type segment review

On the basis of type, the anti-viral therapies market is classified into generic drugs and branded drugs. The branded drugs segment was a major revenue contributor to the anti-viral therapies market in 2018 and is expected to continue its dominance throughout the forecast period, owing to availability of large number of branded drugs for treating various viral infections. Furthermore, higher prescription rate accompanied with higher drug prices is ultimately resulting in high revenue generation. 

Anti-Viral Therapies Market
By Type
Your browser does not support the canvas element.

Branded drugs segment is projected as one of the most lucrative segment.

Mechanism of action segment review

On the basis of mechanism of action, it is divided into nucleotide polymerase inhibitors, reverse transcriptase inhibitors, protease inhibitors, and others. The reverse transcriptase inhibitors segment is expected to grow at the fastest CAGR during the forecast period, owing to increase in FDA drug approvals for treating viral infections by reverse transcriptase inhibitor mechanism.

North America dominated the global antiviral therapies market in 2018 and is expected to continue its dominance throughout the forecast period, owing to growth in incidences of infectious diseases across the region. For instance, as per the data published by CDC (Centers for Disease Control and Prevention), in 2020, the number of diagnoses of HIV infection in the U.S. were 38,281 (2017) and number of new hepatitis A, B, and C were 3,365, 3,409, and 4,225, respectively in 2017. Moreover, the number of deaths due to influenza were 6,515. In addition, the presence of well-established pharmaceutical players that are involved in the manufacturing of the anti-viral therapies and increase in awareness among the population are expected to drive the anti-viral therapies market growth in this region.

Anti-Viral Therapies Market
By Mechanism Of Action
Your browser does not support the canvas element.

Nucleotide polymerase inhibitor segment holds a dominant position in 2018 and would continue to maintain the lead over the forecast period.

Comprehensive competitive analysis and profiles of major market players such as F. Hoffmann-La Roche Ltd., Gilead Sciences, GlaxoSmithKline, Bristol-Myers-Squibb, Abbott Laboratories, AstraZeneca plc, AbbVie Inc., Aurobindo Pharma Limited, Johnson & Johnson, and Merck & Co., Inc. are provided in this report.

Key Benefits For Stakeholders

  • The anti-viral therapies market share and analysis is based on a comprehensive analysis of key developments in the biosensors industry.

  • The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the global anti-viral therapies market.

  • The study provides an in-depth analysis of the anti-viral therapies market trends to elucidate the imminent investment pockets.

  • The global anti-viral therapies market trends are studied from 2018 to 2026.

  • Information about the key drivers, restrains, and opportunities and their impact analysis on the anti-viral therapies market size is provided.

  • Porter’s five forces analysis illustrates the potency of the buyers and suppliers operating in the industry.

  • The quantitative analysis of the global anti-viral therapies market from 2019 to 2026 is provided to determine the market potential.

Anti-Viral Therapies Market Report Highlights

Aspects Details
icon_5
By Application
  • HIV
  • Hepatitis
  • Herpes Virus
  • Influenza
  • Other Applications
icon_6
By Type
  • Generic Drugs
  • Branded Drugs
icon_7
By Mechanism Of Action
  • Nucleotide Polymerase Inhibitor
  • Reverse Transcriptase Inhibitors
  • Protease Inhibitors
  • Others
icon_8
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (Germany, France, UK, Italy, Spain, Rest of Europe)
  • Asia Pacific  (Japan, China, India, Australia, South Korea, Rest of Asia-Pacific)
  • LAMEA  (Brazil, Saudi, South Africa, Rest of LAMEA)
icon_9
Key Market Players

Merck & Co., Inc., Aurobindo Pharma Limited, Bristol Myers Squibb Company, GILEAD SCIENCES, INC., Johnson & Johnson, AbbVie Inc., AstraZeneca PLC, F. Hoffmann-La Roche Ltd., Abbott Laboratories, GlaxoSmithKline Plc.

Analyst Review

The factors that drivethe growth of the anti-viral therapies market includeupsurge in occurrence of infectious diseases in the developed as well as developing region across the globe. Beside this, the presence of strong pipeline drugs for treating viral infections are expectedto augment the growth of the anti-viral therapies market. In contrast to these factors, treating viral infections can incur huge costs to the patients. Moreover, the ever-changing preferences of the patients toward different therapies such as homeopathy and naturopathy are expected to restrain the development of the market. On the other hand, developing novel therapies by combining different drugs are projected to offer lucrativeopportunities for the expansion of the anti-viral therapies market in the near future.

Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. North America is dominating the global antiviral therapies market in 2018 and is expected to continue its dominance throughout the forecast period, owing to growth inincidences of infectious diseases across the region. Whereas, Asia-Pacific is expected to grow at the fastest CAGR during the forecast period due to presence of several generic pharmaceutical players and increase in investmentsfor drug development in South Asian countries. 

Author Name(s) : Snehal Manjrekar| and Onkar Sumant | Roshan Deshmukh
Frequently Asked Questions?

The total market value of Anti-viral Therapies Market is $46,213.4 million in 2018.

The forecast period for Anti-viral Therapies Market is 2019 to 2026

The market value of Anti-viral Therapies Market in 2019 is $39,224.6 million

The base year is 2018 in Anti-viral Therapies Market

Top companies such as, F. Hoffmann-La Roche Ltd., Gilead Sciences, GlaxoSmithKline, Bristol-Myers-Squibb, Abbott Laboratories, AstraZeneca plc, held a high market position in 2018.

Nucleotide polymerase inhibitor segment is the most influencing segment growing in the Anti-viral Therapies Market

The key trend in the Anti-viral Therapies Market is increase in the incidence rate of viral infections across the globe which drives the growth of the market.

Asia-Pacific has the highest growth rate in the market which is growing due to the contribution of the following emerging countries such as China and India with a CAGR of 3.3% and 3.0% respectively.

Loading Table Of Content...

Individual sections of the reports are available for purchase.
Would you like to see a breakdown of prices by section?

Anti-Viral Therapies Market

Global Opportunity Analysis and Industry Forecast, 2019-2026